Up to $818 million deal between J&J and Locus Biosciences points to a new path for CRISPR therapies

The up to $818 million deal between Locus Biosciences and Janssen Pharmaceuticals (a division of Johnson & Johnson) that was announced yesterday points toward a new path for CRISPR gene editing technologies and (potentially) the whole field of microbiome-targeted therapies. Based in Research Triangle Park, N.C., Locus is commercializing research…

Continue reading

Blind loyalty

John Chen Tech companies have been the vanguards for pushing corporate culture forward toward “radical transparency.” Mark Zuckerberg works in a fully transparent four-walled glass office surrounded by the rest of Facebook. Valve so everyone can be their own boss. Startup founders host weekly town halls, Friday all-hands, and AMAs.…

Continue reading